Evaluation of salivary endothelin-1 levels in oral squamous cell carcinoma and oral leukoplakia

Regulatory Peptides

Volumn 166, Issue 1-3, 2011, Pages 55-58

  Hoffmann, Renata R ^a   Yurgel, Liliane S ^a   Campos, Maria M ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Endothelin; Leukoplakia; Oral cancer; Oral squamous cell carcinoma; Saliva

Indexed keywords

ENDOTHELIN 1;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER REGRESSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GERIATRIC PATIENT; HUMAN; HYPERTENSION; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; SALIVA LEVEL; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ENDOTHELIN-1; FEMALE; HUMANS; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH NEOPLASMS; SALIVA; TUMOR MARKERS, BIOLOGICAL;

EID: 78650171758     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.08.006     Document Type: Article

References (28)

1. Peacock Z.S., Pogrel M.A., Schmidt B.L. Exploring the reasons for delay in treatment of oral cancer. J Am Dent Assoc 2008, 139(10):1346-1352.
2. Martorell-Calatayud A., Botella-Estrada R., Bagán-Sebastián J.V., Sanmartín-Jiménez O., Guillén-Barona C. La leucoplasia oral: definición de parâmetros clínicos, histopatológicos y moleculares y actitud terapêutica. Actas Dermosifiliogr 2009, 100:669-684.
3. Warnakulasuriya S., Johnson N.W., van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007, 36:575-580.
4. van der Waal I., Axéll T. Oral leukoplakia: a proposal for uniform reporting. Oral Oncol 2002, 38:521-526.
5. Girod S.C., Pfeiffer P., Ries J., Pape H.-D. Proliferative activity and loss of function of tumour suppressor genes as "biomarkers" in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1998, 36:252-260.
6. Mithani S.K., Mydlarz W.K., Grumbine F.L., Smith I.M., Califano J.A. Molecular genetics of premalignant oral lesions. Oral Dis 2007, 13:126-133.
7. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
8. Levin E.R. Endothelins. N Engl J Med 1995, 333:356-363.
9. Kusserow H., Unger T. Vasoacitive peptides, their receptors and drug development. Basic Clin Pharmacol Toxicol 2004, 94:5-12.
10. Motte S., Mcentee K., Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006, 110:386-414.
11. Bhalla A., Haque S., Taylor I., Winslet M., Loizidou M. Endothelin receptor antagonism and cancer. Eur J Clin Invest 2009, 39(S2):74-77.
12. Watts S.W. Endothelin receptors: what's new and what do we need to know?. Am J Physiol Regul Integr Comp Physiol 2010, 298(2):R254-R260.
13. Guise T.A., Yin J.J., Mohammad K.S. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003, 97(S3):779-784.
14. Russo A., Bronte G., Rizzo S., Fanale D., Di Gaudio F., Gebbia N., et al. Anti-endothelin drugs in solid tumors. Expert Opin Emerg Drugs 2010, 15(1):27-40.
15. Bagnato A., Spinella F., Rosanò L. Emerging role of the axis in ovarian tumor progression. Endocr Relat Cancer 2005, 12:761-772.
16. Bagnato A., Spinella F., Rosanò L. The endothelin axis in cancer: the promise and the challenges of molecularly target therapy. Can J Physiol Pharmacol 2008, 86:473-484.
17. Bagnato A., Rosanò L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008, 40:1443-1451.
18. Awano S., Dawson L.A., Hunter A.R., Turner A.J., Usmani B.A. Endothelin system in oral squamous carcinoma cells: specific siRNA targeting of ECE-1 blocks cell proliferation. Int J Cancer 2006, 118:1645-1652.
19. Pickering V., Jordan R.C.K., Schmidt B.L. Elevated salivary endothelin levels in oral cancer patients - a pilot study. Oral Oncol 2007 Jan, 43(1):37-41.
20. Barton M., Yanagisawa M. Endothelin: 20years from discovery to therapy. Can J Physiol Pharmacol 2008, 86:485-498.
21. Pickering V., Gupta R.J., Quang P., Jordan R.C., Schmidt B.L. Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice. Eur J Pain 2008, 12(3):293-300.
22. Schmidt B.L., Pickering V., Liu S., Quang P., Dolan J., Connelly S.T., Jordan R.C. Peripheral endothelin A receptor antagonism attenuates carcinoma induced pain. Eur J Pain 2007, 11:406-414.
23. Quang P.N., Schmidt B.L. Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice. Pain 2010, 149(2):254-262.
24. Nagler R.M. Saliva as a tool for oral cancer diagnosis and prognosis. Oral Oncol 2009, 45:1006-1010.
25. Shpitzer T., Bahar G., Feinmesser R., Nagler R.M. A comprehensive salivary analysis for oral cancer diagnosis. J Cancer Res Clin Oncol 2007, 133(9):613-617.
26. Xiang S., Denver R., Bailey M., Krum H. Physiologic determinants of endothelin concentrations in human saliva. Clin Chem 2003, 49(12):2012-2019.
27. Gössl M., Lerman A. Endothelin: beyond a vasoconstrictor. Circulation 2006, 113(9):1156-1158.
28. Lam H.-C., Lo G.-H., Lee J.-K., Lu C.-C., Chu C.-H., Sun C.-C., et al. Salivary immunoreactive endothelin in patients with upper gastrointestinal diseases. J Cardiovasc Pharmacol 2004, 44(S1):S413-S417.